Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 14, 2020 07:00 ET | Source: Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals Provides 2020 Update and Outlook

EXTON, Pa., Jan. 14, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), or Idera or the Company, today is providing an update on its tilsotolimod clinical development program and...
December 23, 2019 09:15 ET | Source: Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals Announces Private Placement Up To $97.7 Million

EXTON, Pa., Dec. 23, 2019 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), or the Company, announced today it is entering into an agreement with funds affiliated with an institutional...
November 06, 2019 16:01 ET | Source: Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2019 Financial Results

EXTON, Pa., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera”) (NASDAQ: IDRA), a clinical-stage biopharmaceutical company focused on the development, and ultimately the...
October 21, 2019 07:00 ET | Source: Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals Announces New U.S. Patent For Tilsotolimod Through September 2037

EXTON, Pa., Oct. 21, 2019 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), or the Company, announced today that the U.S. Patent and Trademark Office will issue on November 5, 2019...
September 30, 2019 07:30 ET | Source: Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals Announces Initiation of the ILLUMINATE-206 Trial Evaluating Tilsotolimod in Combination with Nivolumab and Ipilimumab for the Treatment of Solid Tumors

EXTON, Pa., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) announced today the initiation of a phase 2 trial, ILLUMINATE-206 which will evaluate tilsotolimod, a...
September 04, 2019 07:00 ET | Source: Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals Announces Immuno-Oncology Clinical Research Collaboration with AbbVie

EXTON, Pa., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) announced today that they have entered into an immuno-oncology clinical research collaboration with AbbVie,...
August 30, 2019 12:00 ET | Source: Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals to Present at the Baird 2019 Global Healthcare Conference

EXTON, Pa., Aug. 30, 2019 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today announced that the company will present at the Baird 2019 Global Healthcare Conference on Wednesday,...
August 08, 2019 09:00 ET | Source: Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2019 Financial Results

EXTON, Pa., Aug. 08, 2019 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera”) (NASDAQ: IDRA), a clinical-stage biopharmaceutical company focused on the development, and ultimately the...
August 06, 2019 16:00 ET | Source: Idera Pharmaceuticals, Inc.

Idera to Release 2019 Second Quarter Results on August 8, 2019

EXTON, Pa., Aug. 06, 2019 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera”) (NASDAQ: IDRA), a clinical-stage biopharmaceutical company focused on the development, and ultimately the...
July 23, 2019 07:30 ET | Source: Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals Announces Appointments of Elizabeth A. Tarka, MD, FACC as Chief Medical Officer and John J. Kirby as Chief Financial Officer

EXTON, Pa., July 23, 2019 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today announced the appointments of Elizabeth A. Tarka, MD, FACC as Chief Medical Officer and the promotion...